Chiral Technologies

Chiral Technologies

Pre-clinical
West Chester, United StatesFounded 1990chiraltech.com

Daicel Chiral Technologies, a subsidiary of Japan's Daicel Corporation, is the world's foremost provider of chiral separation technologies and services. The company pioneered the chiral chromatography industry nearly four decades ago and maintains market leadership through continuous innovation, a portfolio of over 1,200 chiral column products, and unmatched technical expertise. It serves pharmaceutical companies, academic researchers, and other life science sectors—including agrochemicals, veterinary medicine, and flavor/fragrance—by enabling the rapid and cost-effective isolation of single-enantiomer compounds critical for drug development and product innovation.

Founded
1990
Focus
Small MoleculesDrug Delivery

AI Company Overview

Daicel Chiral Technologies, a subsidiary of Japan's Daicel Corporation, is the world's foremost provider of chiral separation technologies and services. The company pioneered the chiral chromatography industry nearly four decades ago and maintains market leadership through continuous innovation, a portfolio of over 1,200 chiral column products, and unmatched technical expertise. It serves pharmaceutical companies, academic researchers, and other life science sectors—including agrochemicals, veterinary medicine, and flavor/fragrance—by enabling the rapid and cost-effective isolation of single-enantiomer compounds critical for drug development and product innovation.

Technology Platform

Proprietary chiral stationary phases (CSPs) for chromatography, including polysaccharide-based, protein-based, and amino acid-based selectors, along with immobilized phases for robust method development and enantiomer separation.

Funding History

2

Total raised: $26.2M

Series A$22MDCVCJul 15, 2022
Seed$4.2MSOSVNov 15, 2020

Opportunities

Growth is driven by the persistent need for enantiomer separation in small-molecule drug development, expansion into adjacent life science markets (agrochemicals, veterinary medicine), and the increasing complexity of novel chemical entities which require advanced chiral separation expertise and tools.

Risk Factors

Key risks include dependence on the pharmaceutical R&D investment cycle, potential technological disruption from new separation methods, and competitive pressure from large chromatography instrument vendors who bundle consumables.
As a division, its strategy is also subject to the priorities of its parent company, Daicel Corporation.

Competitive Landscape

The main competitors are large chromatography vendors like Waters and Agilent, and specialized suppliers like Phenomenex and Regis Technologies. Daicel differentiates itself through its singular focus on chirality, the industry's broadest product portfolio, over 40 years of application knowledge, and a reputation as the technical leader and most trusted partner for solving challenging separations.

Company Info

TypeServices
Founded1990
LocationWest Chester, United States
StagePre-clinical
RevenueRevenue Generating
SIMILAR COMPANIES
BASi Research Products
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
EydisBio
Pre-clinical · Cambridge
3Spine
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile